About: Sunitinib Malate     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
rdfs:label
  • Sunitinib Malate
rdfs:subClassOf
Has_Free_Acid_Or_Base_Form
Has_Target
Concept_In_Subset
Semantic_Type
  • Pharmacologic Substance
Preferred_Name
  • Sunitinib Malate
NSC_Code
  • 736511
UMLS_CUI
  • C1700685
CAS_Registry
  • 341031-54-7
Accepted_Therapeutic_Use_For
  • Gastrointestinal Stromal Tumor; Advanced Metastatic Renal Cell Carcinoma
In_Clinical_Trial_For
  • Metastatic Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Neuro-Endocrine Tumors; Uterine Cancer; Angiosarcoma; Mesothelioma; Pancreatic Carcinoma; Breast Cancer; Colorectal Cancer; Undifferentiated Nasopharyngeal Carcinoma
  • Acute myeloid leukemia; unresectable neuroendocrine tumor; malignant gastrointestinal stromal tumor; breast cancer; metastatic colorectal cancer; prostate cancer
FDA_UNII_Code
  • LVX8N1UT73
Contributing_Source
  • FDA
ALT_DEFINITION
  • A drug used to treat gastrointestinal stromal tumors (GIST) that have not responded to treatment with imatinib mesylate (Gleevec). SU011248 is also used to treat advanced kidney cancer and is being studied in the treatment of other types of cancer. It is a type of tyrosine kinase inhibitor, a type of vascular endothelial growth factor (VEGF) receptor inhibitor, and a type of angiogenesis inhibitor.NCI-GLOSS
PDQ_Open_Trial_Search_ID
  • 299061
PDQ_Closed_Trial_Search_ID
  • 299061
Chemical_Formula
  • C22H27FN4O2.C4H6O5
Legacy_Concept_Name
  • SU11248
FULL_SYN
  • Sunitinib MalatePTDCP32183
  • SUNITINIB MALATEPTFDALVX8N1UT73
  • Sunitinib MalatePTNCI
  • SU11248PTNCI-GLOSSCDR0000492234
  • SutentPTNCI-GLOSSCDR0000492235
  • SU011248PTNCI-GLOSSCDR0000306520
  • SutentBRNCI
  • SU11248CNNCI
  • SU011248CNNCI
  • Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)SNNCI
  • sunitinib malatePTNCI-GLOSSCDR0000468779
  • sunitinibPTNCI-GLOSSCDR0000492233
DEFINITION
  • The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.NCI
code
  • C26673
sameAs
http://linked.open...y/mesh/hasConcept
is Has_Salt_Form of
is sameAs of
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 46 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software